80
Participants
Start Date
November 30, 2011
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
Ribavirin
Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
Mericitabine
Participants will receive mericitabine 1000 mg orally twice daily.
Peginterferon Alfa-2a
Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
Placebo
Participants will receive placebo matching to mericitabine orally twice daily.
Telaprevir
Participants will receive telaprevir 750 mg orally three times daily.
Weill Cornell Medical College, New York
Fondation Hopital Saint Joseph; Gastro-Enterologie, Marseille
ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Divisione Malattie Infettive, Milan
John Hopkins Hospital, Lutherville
McGuire; Veteran Affairs Med Ctr, Richmond
Universitäts Klinikum; Schleswig-Holstein Kiel, Kiel
Hospital Carlos III; Laboratorio de Biologia Molecular, Madrid
Carolina'S Center For Liver Disease, Statesville
Hopital Purpan;Gastro Enterologie Hepatologie, Toulouse
Gastroenterology Group of Naples, Naples
Birmingham Gastro Associates, P.C., Birmingham
Hospital Universitario de Canarias; Servicio de Digestivo, San Cristóbal de La Laguna
UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In, Bologna
Ospedale Cisanello - Az. Osp. Pisana; Unità Operativa Di Gastroenterologia Ed Epatologia, Pisa
Hopital Claude Huriez;Gastro Enterologie, Lille
Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt am Main
Saint Louis University Gastroenterology & Hepatology; Clinical Research Unit, St Louis
Baylor Uni Medical Center; Division Of Hepatology/Transplantation; Annette C. and Harold C. Simmons, Dallas
Uniklinik Freiburg; Abteilung Innere Medizin II, Freiburg im Breisgau
VA Long Beach Healthcare System, Long Beach
UCSD Antiviral Research Center, San Diego
Kaiser Permanente Sacramento Medical Center, Sacramento
Harborview Medical Center, Seattle
Yale University, New Haven
Metrowest Medical Center, Framingham
Uni of Cincinnati College of Medicine; Div. of Digestive Diseases, Cincinnati
Gordon & Leslie Diamond Health Care Centre; Dept. of Medicine - Division of Gastroenterology, Vancouver
GI Research Institute; Gastroenterology & Hepatology, Vancouver
Percuro Clinical Research Ltd., Victoria
Winnipeg Regional Health Authority; Section of Hepatology, Winnipeg
University Health Network - Toronto Western Hospital; Hepatology, Toronto
Toronto Digest. Disease Asso., Woodbridge
McGill University, Montreal Chest Institute; Viral and other Infectious, Montreal
Hospital Universitari Vall d'Hebron; Departamento de Enfermedades Infecciosas, Barcelona
Hospital Clinic I Provincial; Servicio de Digestivo, Barcelona
Royal Bournemouth Hospital, Gastroenterology, Dorset
King'S College Hospital; Institute of Liver Studies, London
St George's Hospital, London
Imperial College Healthcare NHS Trust; Hepatology Clinical Research Facility, London
Hoffmann-La Roche
INDUSTRY